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Background: During the last two decades the use of laparoscopic resection and a multimodal approach known as
an enhanced recovery programme, have been major changes in colorectal perioperative care. Clinical outcome
improves using laparoscopic surgery to resect colorectal cancer but until recently no multicentre trial evidence had
been reported regarding whether the benefits of laparoscopy still exist when open surgery is optimized within an
enhanced recovery programme. The EnROL trial (Enhanced Recovery Open versus Laparoscopic) examines the
hypothesis that laparoscopic surgery within an enhanced recovery programme will provide superior postoperative
outcomes when compared to conventional open resection of colorectal cancer within the same programme.
Methods/design: EnROL is a phase III, multicentre, randomised trial of laparoscopic versus open resection of colon
and rectal cancer with blinding of patients and outcome observers to the treatment allocation for the first 7 days
post-operatively, or until discharge if earlier. 202 patients will be recruited at approximately 12 UK hospitals and
randomised using minimization at a central computer system in a 1:1 ratio. Recruiting surgeons will previously have
performed >100 laparoscopic colorectal resections and >50 open total mesorectal excisions to minimize
conversion. Eligible patients are those suitable for elective resection using either technique. Excluded patients
include: those with acute intestinal obstruction and patients in whom conversion from laparoscopic to open
procedure is likely. The primary outcome is physical fatigue as measured by the physical fatigue domain of the
multidimensional fatigue inventory 20 (MFI-20) with secondary outcomes including postoperative hospital stay;
complications; reoperation and readmission; quality of life indicators; cosmetic assessments; standardized
performance indicators; health economic analysis; the other four domains of the MFI-20. Pathological assessment of
surgical quality will also be undertaken and compliance with the enhanced recovery programme will be recorded
for all patients.
Discussion: Should this trial demonstrate that laparoscopic surgery confers a significant clinical and/or health
economic benefit this will further support the transition to this type of surgery, with implications for the training of
surgeons and resource allocation.
Trial registration: ISRCTN48516968.
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Figure 1 Randomisation schema.
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During the last 20 years laparoscopic colorectal cancer
resection has developed, improving short term clinical
outcomes [1-3] while providing equivalent oncological
results [4-8]. Some authors [9-11] have reported 3–4 day
median postoperative hospital stays after laparoscopic
surgery, whereas previously it would have been >10 days
[12,13] . Systematic reviews [1,2] document improve-
ments in short term outcomes after laparoscopy, par-
ticularly reduction in complications, postoperative pain
and hospital stay. However despite these reports the pro-
portion of elective colorectal resections performed lap-
aroscopically in England during 2011 was still only
estimated to be 33% (personal communication, MG
Coleman)
The last 12 years have also seen the appearance of
Enhanced Recovery care or Fast Track Surgery. This ap-
plies a multimodal approach to improving care using
evidence based interventions and has even resulted in
mean and median postoperative hospital stays of 3 days
[9,14,15]. Enhanced Recovery care involves precondi-
tioning of patient expectation, modification of surgical
technique with smaller incisions, improved anaesthetic
and fluid replacement practices, better postoperative
pain control, omission of opiates where possible, avoid-
ance of drains and nasogastric tubes, early removal of
urinary catheters, mobilization and feeding immediately
after surgery, early discharge, and expedited review when
necessary. As a result of these developments trials on
enhanced recovery care report reductions in postopera-
tive complications and hospital stay [16-18]. There has
understandably been great interest in the introduction of
enhanced recovery care but it is unclear what proportion
of hospitals have introduced it. We estimate that it will
not have been introduced effectively in more than 50%
of UK hospitals to date.
Given the significant shortening of hospital stay and
decrease in complications resulting from the use of an
Enhanced Recovery Programme (ERP), can laparoscopic
surgery further improve recovery? Two small single
centre studies from Denmark and England [10,19] pro-
vided conflicting results. The Danish study reported
3 day median postoperative hospital stays in both arms,
whereas the English trial showed a significant reduction
in median hospital stay and readmission rate for the lap-
aroscopic group. It is, therefore, unclear whether optimal
results following elective colorectal resection are
achieved by laparoscopy or by using open surgery which
has been optimized within an Enhanced Recovery
Programme. To answer this question the EnROL trial
has been designed to examine outcomes in a multicentre
setting. This study examines the hypothesis that laparo-
scopic surgery within an ERP will provide superior post-
operative outcomes when compared to conventionalopen resection of colorectal cancer within the same
programme.Methods/design
Study design
The EnROL trial (Enhanced Recovery Open versus Lap-
aroscopic) is a phase III, multicentre, randomised con-
trolled trial, with blinding of patients and outcome
observers during the first week post-operatively or until
the date of postoperative discharge if earlier. Patients will
be randomised between open and laparoscopic surgery,
with both groups treated within an ERP, see Figure 1. The
trial is being run at 12 centres in the UK which encompass
a mix of rural and urban populations, treated within dis-
trict general and specialist hospitals. In contrast to most
previous laparoscopic colorectal trials the surgeons will
have extensive experience of both laparoscopic and open
surgery, having completed at least 100 laparoscopic colo-
rectal resections and 50 open total mesorectal excisions
prior to participating in the study. This should minimise
the number of operations that will need to be converted
to the open approach. Additionally surgeons will be pro-
vided with video recordings of standardized laparoscopic
procedures prepared for the UK laparoscopic colorectal
preceptorship programme.
The primary endpoint is patient reported physical fa-
tigue measured by the physical fatigue domain of the
multidimensional fatigue inventory 20 (MFI-20) [20] at
4 weeks after surgery. The secondary endpoints include
postoperative hospital stay; 30 day and in-hospital com-
plications; 30 day re-admission and re-operation rates;
the other four domains of the MFI-20; a generic and
cosmetic health related quality of life assessments [21-23];
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of resource use.
The study population is patients of age 18 and above
who require elective resection of colonic or rectal cancer
and are suitable for laparoscopic surgery. Exclusions to
trial entry are acute intestinal obstruction, previous com-
plex laparotomies, emergency admission and pregnancy.
Patients are also ineligible when, in the opinion of the
treating surgeon, conversion to open surgery is likely
(such as in rectal cancer when preoperative imaging sug-
gests tumour is present at the resection margin – ‘threa-
tened margin’). Preoperative identification of the
inability to insert an epidural catheter is also an exclu-
sion criterion, as it would prevent patients who require
it receiving postoperative epidural analgesia.
The EnROL trial has been approved by the National
Research Ethics Service Committee South Central -
Oxford B (REC reference: 07/H0605/150). The trial is
co-ordinated by the Oncology Clinical Trials Office
(OCTO) at the University of Oxford, with statistical
support from the Centre for Statistics in Medicine,
which together form Oxford Clinical Trials Research
Unit (OCTRU). OCTRU is a UKCRN Registered Clin-
ical Trials Unit. The trial is sponsored by the University
of Oxford and North West London Hospitals NHS
Trust. The Data Safety and Monitoring Committee
and Trial Steering Committee, which includes a pa-
tient representative, will meet regularly in order to
oversee the trial appropriately. Funding has come
principally from the Bobby Moore Fund, Cancer Re-
search UK (CR-UK) (Ref number: CRUK/07/019).
Ethicon Endo-surgery have provided additional fund-
ing to facilitate provision of wound dressings and col-
lection of pathology material.Randomisation
Following consent, eligible patients will be randomised
in a 1:1 ratio to open or laparoscopic resection using a
central computer system at the Oncology Clinical Trials
Office. Simple randomisation will be used for the first 50
patients then minimization with a random element (0.8)
[25]. The stratification factors used in the minimization
are hospital, cancer site (colon/rectum) and age (<66 years,
66–75 years, >75 years). To facilitate blinding of outcome
observers the randomisation allocation will be sent directly
to the patient’s surgeon via email and will not be made
available to the site staff member completing the random-
isation process.Intervention
Surgery is to be carried out by one of the centre’s trial-
accredited surgeons no later than 6 weeks after
randomisation.Surgery should be performed in a standard fashion by
the trial surgeon(s) at each site, the only difference being
the method of access. Rectal tumours within 10 cm of
the anal verge should be treated by total mesorectal ex-
cision accompanied, whenever possible, by preservation
of the hypogastric nerves. Tumours are defined as being
rectal when at or within 15 cm of the anal verge on rigid
sigmoidoscopy, performed with the patient awake on
their left side. Conversion is defined as the inability to
complete the dissection fully laparoscopically, including
the vascular division, and it usually but not always,
requires the use of a larger incision than that needed to
remove the specimen.
Blinding
Patients and outcome observers are to be blinded to
the randomisation allocation until 7 days after sur-
gery or the day of discharge if earlier. To facilitate
this large Allevyn™ adhesive dressings will be pro-
vided for all trial patients. In addition, centres should
ensure that all patient records which detail the ran-
domisation allocation are stored in a sealed envelope
within the patient’s notes until after the patient is
unblinded.
Blinding is an important design feature of randomised
controlled trials, reducing the risk of several forms of
bias including reporting bias and observer bias. A suc-
cessfully implemented blinding protocol improves the
validity of trial results, however the success of blinding
is infrequently tested or reported in randomised con-
trolled trials. To investigate the role and success of
blinding in surgical randomised controlled trials, and its
impact on patient experience, the trial protocol was
amended to include collection of quantitative data about
the success of blinding using the Bang Blinding Index
[26]. This statistical measure calculates the proportion of
un-blinded patients (and research staff ) in the trial by
asking them to state to which arm of the study they be-
lieve they (their patient) have been allocated.
Enhanced recovery care
The standardized perioperative care protocol (Enhanced
Recovery Programme) is outlined in Table 1. It is pos-
sible for individual centres to amend this programme
provided the treatment is standardized irrespective of
randomisation, and the Trial Office is notified prior to
the centre opening to recruitment. Compliance with the
components of the Enhanced Recovery Programme will
be recorded for all patients.
Measurement of outcomes
Primary endpoint
The primary endpoint is physical fatigue 4 weeks
after surgery as measured using the physical fatigue
Table 1 Standardised Enhanced Recovery Programme for the EnROL Trial
Before admission Conditioning of expectations of patient and carer by receipt of oral and written information
at a dedicated preadmission visit, or by telephone counselling, with provision of a
dedicated booklet or video sent by post.
Meeting with stoma nurse if stoma anticipated.
Identification of factors that might delay discharge and consideration of solutions
e.g. provision of support
when discharged if living alone.
Co-morbid risk assessment: optimised pre-morbid health status.
Day before surgery Avoidance of oral bowel preparation except in patients undergoing total mesorectal excision
(TME) and reconstruction.
Nutrition: three high protein/high calorie drinks if receiving oral bowel preparation.
Day of surgery Pre-operatively Preoperative oral carbohydrate loading to be given 2-4 hours prior to anaesthesia,
using 200ml of fluid
containing 12.5g/100ml CHO with a proven safety profile.
Avoidance of long acting sedative medication from midnight prior to surgery.
In theatre Activation of thoracic epidural (T6-11) prior to skin incision.
Avoidance of abdominal drains at primary operation.
Avoidance of nasogastric drainage in the immediate postoperative period.
Total volume of IV fluid < 3000ml.
The use of upper body forced air heating intraoperatively.
Local anaesthetic infiltration to the largest wound in minimal access surgery.
Open surgery: small transverse or curved incisions when possible.
After theatre Oral intake of ≥ 800ml fluid (including oral nutritional supplements) postoperatively on
the day of surgery,
before midnight.
≥ 200ml oral nutritional supplement postoperatively on the day of surgery, before midnight.
Mobilisation by walking or sitting in a chair.
First Postoperative day from
midnight – midnight (Day 1)
≥ 2 units of oral nutritional supplement taken.
Termination of IV fluid infusion.
Intake and tolerance of solid food.
Intake of lactulose or a magnesium preparation to enhance bowel movements.
Use of thoracic epidural analgesia.
Mobilisation (out of bed) for at least 6 hours.
Provided patient mobile, termination of urinary drainage on day 1, except after TME when it may be
preferable to leave it until day 3
Assisted mobilisation – 4 × 60m walks.
Second Postoperative day from
midnight – midnight (Day 2)
Pain relief: termination of the thoracic epidural analgesia.
Use of a multi-modal analgesic regime at, or before, discontinuation of thoracic epidural analgesia
e.g. paracetamol and non steroidal anti-inflammatory or equivalent.
Termination of urinary drainage on day 2 or earlier, except after TME when it may be
preferable to leave it
until day 3.
Discharge Aim for discharge day 2-3 for colonic and proximal rectal resection; day 5 when a
stoma fashioned.
Discharge Criteria: patients must be tolerating normal food, mobilising independently
and be managed on
oral analgesics to fulfil discharge criteria.
Follow up: provision of hospital contact numbers to allow discussion of problems;
expedited review on
ward if problems within 2 weeks of surgery.
Review in out patient clinic at two weeks post operation.
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Table 2 Standard definitions of complications for assessing morbidity of trial patients
Category Definition
Cardiorespiratory Respiratory failure - requiring mechanical ventilation
Cardiac failure: cardiac index < 2 litres per m2 (treated first by fluid resuscitation and if no response by
inotropic or vasoconstrictive medication)
Pulmonary oedema - radiological diagnosis
Arrhythmia - ECG changes requiring medical treatment and/or electroconversion
Pleural fluid - radiographic diagnosis
Acute myocardial infarction - electrocardiographic diagnosis
Acute renal failure - requiring haemofiltration
Stroke with neurological symptoms
Pulmonary embolism
Distal ischaemia
Deep vein thrombosis - requiring duplex, radiological or other confirmation
Other cardiorespiratory
Surgical Unexpected blood loss >0.5 litres during operation
Bowel perforation
Ureteric damage
Wound dehiscence involving separation of deep abdominal wall closure
Postoperative bleeding - overt blood loss requiring > 2 litre transfusion with a normal clotting profile.
Delayed oral intake - intravenous fluids > 1 week owing to postoperative ileus
Bowel obstruction requiring reoperation
Anastomotic leakage defined within 30 days of surgery radiologically (demonstration on abdominal CT with
oral contrast, MRI or by contrast enema), surgically (visual evidence of faecal leakage at reoperation)
or at autopsy (presence of a disrupted anastomosis).
Necrosis of stoma - requiring surgery
Aspiration Pneumonia - radiological diagnosis with appropriate history
Other surgical
Infective Sepsis - pyrexia > 38 oC, septic focus or positive blood culture
Postoperative peritonitis - clinical diagnosis
Abdominal abscess - ultrasonograpy, computed tomography or operative diagnosis
Necrotising fasciitis
Wound infection - defined as any one of the following: (modified from reference 26)
1. Purulent discharge or the aspiration of pus
2. Erythema or localised swelling requiring antibiotics or surgical drainage, unless the drainage is clear
and negative on culture i.e. a seroma
3. A diagnosis of a wound infection made by a doctor.
4. Report of wound discharge by the patient unless it is proven to be uninfected
Chest infection - radiological diagnosis or empyema
Urinary tract infection
Disseminated intravascular coagulation
Other infective complication
Major morbidity is defined as any of the following occuring within the hospital admission or 30 days of surgery: haemorrhage (requiring transfusion),
any re-operation or readmission, anastomotic leakage, wound dehiscence, sepsis requiring at least high dependency support, HDU stay of > 5 days,
unplanned admission to Intensive or Coronary Care Unit and death.
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(MFI-20). The MFI-20 is a 20-item self-report instru-
ment designed to measure fatigue. It covers thefollowing dimensions: general fatigue, physical fatigue,
reduced activity, reduced motivation and mental
fatigue.
Table 3 Time points for the collection of patient reported and functional outcome data
Questionnaire/
Assessment
Data Collection Time Point
Pre
Operative*
Post-operative
4 weeks 3 months 6 months 12 months
MFI-20 X X X X
SF-36 X X X X
EQ-5D X X X X
Health Economics X X X X
Body Image X X X
SPIs X X X X
* To be completed not more than 4 weeks prior to surgery.
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Postoperative hospital stay
Postoperative hospital stay will be reported, counting the
day of operation as day zero.
Complications, re-admission, re-operation and mortality
rates
30 day morbidity will be assessed at 30 days post-
operatively by the centre’s Research Nurse using a stan-
dardised definition of complications which have been
modified from Lang et al. (2001) who reported a doub-
ling of cost and hospital stay associated with postopera-
tive complications [27]. The standard definitions of
complications are detailed in Table 2. 30 day re-admission
and re-operation rates, along with 30 day and in-hospital
mortality will also be recorded.
Patient reported and functional outcomes
Health related quality of life will be assessed using the
SF-36 questionnaire [21]. Quality of life will also be ana-
lysed with the EQ-5D. Cosmetic outcomes will be per-
formed using a body image assessment [23,28]. Time
points for the completion of these questionnaires are
shown in Table 3.
An observer assessment of physical function will be
measured using standardized, objective performance
indicators (SPIs) [24] which comprise a test of lower
limb strength, balance and endurance. SPIs will be mea-
sured prior to surgery and then at 4 weeks, 3 and
6 months postoperatively. The tests differs from those
described by Guralnik et al., in that patients will be mea-
sured for walking speed along a 10 metre, instead of 8
foot course, with a 61.5 cm (2 foot) clear zone at each
end as originally described.
Health economics outcomes
Health Economics questionnaires and EQ-5D will be
completed by all patients providing information
about the use of healthcare post-operatively for
6 months. Data collected will include GP surgery vis-
its, GP home visits, in- patient stays, out-patientsvisits, District Nurse visits, physiotherapy and stoma
nurse usage. Data will also be collected from the trial
records to calculate the relative cost of the operative
and peri- operative periods. Costs to be calculated in-
clude in-patient hotel costs, in-patient treatments costs
(including re-admission and re-operation within 30 days
and convalescent care), operating theatre costs and drug
costs [29].Other domains of the MFI
The other four domains general fatigue, reduced activity,
reduced motivation and mental fatigue will be analysed.Follow up & data collection
Patients will be seen at 2 and 4 weeks and then at 3 and
6 months post operatively. Follow up data will also be
collected at 12 months after surgery. Research staff at
the centres will collect the data and submit it to the
Trial Office via the EnROL electronic data capture
website.Pathology
Resection specimens will be photographed to judge the
quality of surgery of the mesorectum [30], anal sphinc-
ters, [31,32] and the mesocolon [33] [34]. Dissection will
be carried out according to the trial protocol using cross
sectional slicing, careful inspection for distance of extra-
mural spread, lymph nodes, extramural vascular invasion
and peritoneal involvement. TNM version 5 and modi-
fied Dukes grading including C2 and stage D will be
used and regression grading and data collected by proto-
col. The distance to the high tie from the tumour will be
recorded. Quality will be assessed locally and centrally
with the addition of measurements of the specimens’
physical characteristics performed centrally. The quality
of laparoscopic and open surgery will be compared to
previous studies to facilitate assessment of the results of
the trial.
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Sample size: The original sample size calculation
required 266 patients (133 per treatment arm) to allow
90% power to detect a difference in the primary out-
come of fatigue (as measured by physical fatigue domain
of the MFI-20) of 0.45 standard deviations at p = 0.05
(two-sided). This includes a loss to follow up of 15% and
a conversion rate of 8% from laparoscopic to open sur-
gery. Following slower than expected recruitment the
power was lowered to 80% in order to complete the
study in a timely manner. With all other variables
remaining the same the subsequent sample size of 202
(101 per treatment arm) is required. Additionally the
study is powered to detect a 3 day difference in hospital
stay at 80% power and p = 0.05 (two-sided).Analysis
All analyses will be on an intention-to-treat basis.
The primary outcome will be physical fatigue as mea-
sured by the physical fatigue domain of the MFI-20 at
four weeks post operatively. If the primary outcome is
normally distributed it will be compared using a t-test,
ANCOVA adjusting for the minimization factors (pri-
mary analysis) and ANCOVA with further adjustment
for prognostic factors.
Physical fatigue will also be compared at three and six
months, the remaining quality of life variables at 4 weeks,
3 and 6 months, and the cosmetic outcome at 6 and
12 months, using the same analyses as for the primary
outcome. Physical fatigue will be adjusted for the level of
physical fatigue prior to surgery. The other measures of
fatigue will also be reported.
For all continuous outcome variables, if there is severe
departure from Normality the first approach will be
transformation. If the data cannot be transformed to
Normality, a Mann–Whitney test will be used. In the
latter case no adjustment will be made for the
minimization or prognostic factors.
Hospital stay will be compared using Kaplan Meier
plots and log rank tests. The complications, re-operation
and re-admission data will be binary and will hence be
compared between the randomisation groups using a chi
square test (or Fisher exact test if the data is sparse).
Quality of Life assessments at 4 weeks as measured by
the SF-36 will be analysed as suggested in the SF-36
manual, comparison between treatments will use t-test
and ANCOVA to adjust for prognostic factors. Mixed-
effects models of repeated measures will be used to
evaluate longitudinal comparisons (4 weeks, 3 months
and 6 months).
The other four domains of the MFI will be analysed in
the same way as the physical fatigue domain specified in
the primary analysis.The comparison between treatment groups of stan-
dardised performance indicators will use t-tests and
ANCOVA adjusting for prognostic factors and
baseline.
The tumour stage, quality of surgery grade, the phys-
ical measurements and the frequency of Dukes’ C2 cases
will be compared between groups.
Analysis of the health economic data will be under-
taken separately by those involved in the health eco-
nomic analysis. Costs will be estimated from the
perspective of the UK NHS and health benefits
expressed in terms of quality-adjusted life-years
(QALYs). The cases where laparoscopic surgery may be
considered cost effective will be pre-defined and the
mean differential costs and QALYs will be calculated in
order to assess whether any of these conditions are satis-
fied. The relative costs of the operative and peri-opera-
tive period will be derived for all trial patients including
the cost of consumables that are likely to differ between
the two surgical procedures.
QALYs will be calculated for each patient in the trial,
on the basis of their responses to the EQ-5D pre-
operatively, at one month, three months and six months.
Given that the time horizon of the analysis will be less
than one year, total costs and QALYs remain undis-
counted. To account for the skewed nature of the data,
95% CIs for the differential costs and QALYs will be esti-
mated using bootstrapping methods. Missing data will be
imputed using a multivariate multiple imputation proced-
ure (Solas 3.0).
Statistical analysis will be undertaken using Stata
(StataCorp LP).
Discussion
The EnROL trial has been set up to examine the hypoth-
esis that laparoscopic surgery improves outcome when
compared to open surgery for colorectal cancer resec-
tion, even when both methods are optimized within an
ERP. Prior to 2011 there had only been two small studies
examining this issue [10,19] and they reported conflict-
ing results. Other trials reporting an improvement in
clinical outcome following laparoscopic surgery did not
use an enhanced recovery programme to optimize the
open group [1,2,4].
In 2011 the LAFA trial [35] published outcomes com-
paring the two approaches to surgery +/− an ERP. In
this study of patients having segmental colectomy, total
hospital stay was reduced following laparoscopic surgery
when compared to open surgery. There are significant
differences between the EnROL and LAFA trials that
warrant continuation of EnROL. The EnROL trial only
involves very experienced laparoscopic surgeons; it will
include patients with rectal carcinoma; it will not in-
clude patients with benign diagnoses; and there will be
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care, as happened in the LAFA trial.
The involvement in this trial of surgeons experienced
in laparoscopy is important as it minimises the % con-
version rate to open surgery, thus providing a more
homogeneous laparoscopic group of patients (given the
intention to treat analysis) and increasing the potential
to demonstrate differences in outcome. The choice of
100 prior laparoscopic resections to enable surgeons to
contribute to EnROL is both intuitive and based on
data from studies examining the acquisition of surgical
competence with this approach [36]. Rectal carcinoma
has been included in the EnROL trial as rectal resec-
tion is often more difficult than colonic surgery and
also more demanding laparoscopically. As a result only
one large randomised trial has been reported to date
examining outcomes following resection of both high
and low rectal cancers [6]. Generally hospital stay fol-
lowing rectal surgery is longer than after colonic sur-
gery and therefore the potential to improve outcome
after rectal surgery is greater, assuming laparoscopy
decreases complications.
Patients with benign diagnoses have not been included
in this study as in general they are younger and therefore
fitter. By restricting the study to the treatment of cancer,
and therefore an older age group who are generally less
fit, it is likely surgery will have a greater impact on the
patients -manifesting itself as a higher incidence of post-
operative complications. The use of laparoscopic surgery
has been shown to decrease postoperative complications
[1,2] and the choice of only malignancy in the treatment
group should highlight the potential benefits of this
approach.
The primary endpoint of physical fatigue as measured
by the Multidimensional Fatigue Inventory 20 (MFI-20)
was chosen in order to provide a more global assess-
ment of recovery than the normally used measure of
postoperative hospital stay. In the past multicentre ran-
domised trials looking at laparoscopic surgery have
rarely found a difference in outcome when using a qual-
ity of life indicator. One exception was a trial of
laparoscopic versus open donor nephrectomy that
demonstrated a benefit to laparoscopy using both the
MFI-20 and the SF-36 questionnaires [37]. The EnROL
trial differs to many in that the surgeons are more
experienced laparoscopic practitioners and thus we ex-
pect to see a lower conversion rate to open surgery and
a more homogeneous ‘laparoscopic’ group of patients.
The potential to detect a significant difference in out-
comes will therefore be more likely than in some previ-
ous studies.
Currently laparoscopic colorectal resection costs more
than open surgery because of the disposable equipment
that is required. Many surgeons who practise conventionalopen colorectal surgery do not have the skills that would
allow them to take on the minimal access technique and
they will need extensive retraining in laparoscopy if they
are to provide this new approach, which again has cost
implications. In addition the procedure can take longer to
perform than equivalent open operations, at least in the
early stages of a surgeon’s laparoscopic experience. For all
these reasons and also the potential for laparoscopic sur-
gery to improve clinical outcomes when compared to
open surgery, it is important that the EnROL trial exam-
ines this question within a multicentre setting.Abbreviations
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